Evidence map›Paper›PMID 35059996›Full record

ReviewCurrent oncology reports2022

New Developments in Gastric Neuroendocrine Neoplasms.

Klaire Exarchou, Nathan A Stephens, Andrew R Moore, Nathan R Howes, D Mark Pritchard

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Modern Management of Gastric Neuroendocrine Neoplasms.Current treatment options in oncology · 2024
    Review
  9. BeyondMolecular therapy oncolytics · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. [Management of Type 1 Gastric Neuroendocrine Tumors Less than 10 mm in Diameter].The Korean journal of helicobacter and upper gastrointestinal research · 2023
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Klaire ExarchouDepartment of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, The Henry Wellcome Laboratory, Nuffield Building, Crown Street, Liverpool, L69 3GE, UK.
Nathan A StephensDepartment of Upper Gastrointestinal Surgery, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Andrew R MooreDepartment of Gastroenterology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Nathan R HowesDepartment of Upper Gastrointestinal Surgery, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
D Mark PritchardDepartment of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, The Henry Wellcome Laboratory, Nuffield Building, Crown Street, Liverpool, L69 3GE, UK. mark.pritchard@liverpool.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewGastric neuroendocrine neoplasms (g-NENs) are a rare type of stomach cancer. The three main subtypes have different pathogeneses, biological behaviours and clinical characteristics, so they require different management strategies. This article will provide an overview of g-NENs and highlight recent advances in the field. RECENT

findingsMolecular profiling has revealed differences between indolent and aggressive g-NENs, as well as a new somatic mutation responsible for some familial type I g-NENs. Novel biomarkers have been developed which will hopefully improve diagnosis, treatment, risk stratification and follow-up. Patient treatment is also changing, as evidence supports the use of less aggressive options (e.g. endoscopic surveillance or resection) in some patients with more indolent tumours. g-NEN heterogeneity poses challenges in understanding and managing this rare disease. More basic science research is needed to investigate molecular pathogenesis, and future larger clinical studies will hopefully also further improve treatment and patient outcomes.

Indexed as

Neuroendocrine TumorsStomach NeoplasmsHumansAtrophic gastritisCarcinoidEnterochromaffin-like (ECL)-cellGastrinNeuroendocrine tumourstomach

Identifiers

PMID35059996
PMCPMC8831276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.